159 related articles for article (PubMed ID: 11907177)
1. Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase.
Mürdter TE; Friedel G; Backman JT; McClellan M; Schick M; Gerken M; Bosslet K; Fritz P; Toomes H; Kroemer HK; Sperker B
J Pharmacol Exp Ther; 2002 Apr; 301(1):223-8. PubMed ID: 11907177
[TBL] [Abstract][Full Text] [Related]
2. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics of cyclophosphamide, adriamycin and adriamycin prodrug (HMR 1928) using an ex vivo isolated perfused human lung model (IHLP)].
Mürdter TE; Linder A; Friedel G; McClellan M; Bohnenstengel F; Sperker B; Kroemer HK; Toomes H; Freitag L; Fritz P
Pneumologie; 2000 Nov; 54(11):494-8. PubMed ID: 11132546
[TBL] [Abstract][Full Text] [Related]
4. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
[TBL] [Abstract][Full Text] [Related]
5. Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting.
Sperker B; Werner U; Mürdter TE; Tekkaya C; Fritz P; Wacke R; Adam U; Gerken M; Drewelow B; Kroemer HK
Naunyn Schmiedebergs Arch Pharmacol; 2000 Aug; 362(2):110-5. PubMed ID: 10961372
[TBL] [Abstract][Full Text] [Related]
6. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
7. Elucidation of the mechanism enabling tumor selective prodrug monotherapy.
Bosslet K; Straub R; Blumrich M; Czech J; Gerken M; Sperker B; Kroemer HK; Gesson JP; Koch M; Monneret C
Cancer Res; 1998 Mar; 58(6):1195-201. PubMed ID: 9515805
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826).
Woessner R; An Z; Li X; Hoffman RM; Dix R; Bitonti A
Anticancer Res; 2000; 20(4):2289-96. PubMed ID: 10953287
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous high-performance liquid chromatographic determination of a glucuronyl prodrug of doxorubicin, doxorubicin and its metabolites in human lung tissue.
Mürdter TE; Sperker B; Bosslet K; Fritz P; Kroemer HK
J Chromatogr B Biomed Sci Appl; 1998 May; 709(2):289-95. PubMed ID: 9657226
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Berjeaud JM; Guilhot F; Papot S
J Med Chem; 2012 May; 55(9):4516-20. PubMed ID: 22515366
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for sarcoma utilizing adenoviral transfer of the beta-glucuronidase and bax genes and an anthracyline prodrug.
Miller SD; Mohiuddin I; Cao XX; Ozvaran MK; Daniel JC; Roy Smythe W
J Surg Res; 2004 Oct; 121(2):153-8. PubMed ID: 15501454
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin.
Platel D; Bonoron-Adèle S; Dix RK; Robert J
Br J Cancer; 1999 Sep; 81(1):24-7. PubMed ID: 10487608
[TBL] [Abstract][Full Text] [Related]
13. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
[TBL] [Abstract][Full Text] [Related]
14. Antegrade versus retrograde isolated lung perfusion: doxorubicin uptake and distribution in a sarcoma model.
Krueger T; Kuemmerle A; Andrejevic-Blant S; Yan H; Pan Y; Ballini JP; Klepetko W; Decosterd LA; Stupp R; Ris HB
Ann Thorac Surg; 2006 Dec; 82(6):2024-30. PubMed ID: 17126104
[TBL] [Abstract][Full Text] [Related]
15. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
[TBL] [Abstract][Full Text] [Related]
16. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
Bosslet K; Czech J; Hoffmann D
Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
[TBL] [Abstract][Full Text] [Related]
17. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity.
Vingerhoeds MH; Haisma HJ; Belliot SO; Smit RH; Crommelin DJ; Storm G
Pharm Res; 1996 Apr; 13(4):604-10. PubMed ID: 8710754
[TBL] [Abstract][Full Text] [Related]
18. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate.
Fonseca MJ; Jagtenberg JC; Haisma HJ; Storm G
Pharm Res; 2003 Mar; 20(3):423-8. PubMed ID: 12669963
[TBL] [Abstract][Full Text] [Related]
19. Cytostatic lung perfusion by use of an endovascular blood flow occlusion technique.
Furrer M; Lardinois D; Thormann W; Altermatt HJ; Betticher D; Triller J; Mettler D; Althaus U; Burt ME; Ris HB
Ann Thorac Surg; 1998 Jun; 65(6):1523-8. PubMed ID: 9647052
[TBL] [Abstract][Full Text] [Related]
20. Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy.
Weyel D; Sedlacek HH; Müller R; Brüsselbach S
Gene Ther; 2000 Feb; 7(3):224-31. PubMed ID: 10694799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
